Brigatinib对比Crizotinib一线治疗ALK阳性NSCLC的III期ALTA-1L第二次中期分析
Brigatinib在盲法独立评审委员会评估的无进展生存期(PFS)上显著优于Crizotinib(HR 0.49,中位24.0 vs 11.0个月),并延迟了全球健康状况/生活质量恶化,安全性无新信号。
要点
- Brigatinib一线治疗显著改善PFS:BIRC评估HR 0.49,中位24.0 vs 11.0个月。
- Brigatinib延迟生活质量恶化:全球健康状况/QoL评分恶化时间HR 0.70。
- Brigatinib每日一次给药,疗效、耐受性和生活质量均优于Crizotinib。
核心结论
- Brigatinib一线治疗ALK阳性NSCLC在疗效、耐受性和生活质量方面均优于Crizotinib,是 promising 的一线选择。
研究设计与样本
- 主要终点为盲法独立评审委员会(BIRC)评估的PFS,本次为预设的第二次中期分析(150个PFS事件)。
主要发现
- BIRC评估的PFS:Brigatinib组中位24.0个月,Crizotinib组中位11.0个月,HR 0.49(95%CI 0.35-0.68),log-rank P < .0001。
- 研究者评估的PFS:HR 0.43(95%CI 0.31-0.61),中位29.4 vs 9.2个月。
- 全球健康状况/QoL评分恶化时间:Brigatinib组较Crizotinib组延迟,HR 0.70(95%CI 0.49-1.00),log-rank P = .049。
- Brigatinib每日血浆浓度-时间曲线下面积不是PFS的预测因素(HR 1.005,95%CI 0.98-1.031,P = .69)。
- 未出现新的安全性问题。
关键数值与推荐
- Brigatinib给药方案:180 mg每日一次,起始7天为90 mg每日一次导入。
- Crizotinib给药方案:250 mg每日两次。
- 主要终点BIRC评估PFS的HR 0.49(95%CI 0.35-0.68),P < .0001。
临床怎么用
- 对于ALK抑制剂初治的晚期ALK阳性NSCLC患者,Brigatinib每日一次方案可作为一线治疗选择,较Crizotinib显著延长PFS并延迟生活质量恶化。
局限性
- 本次分析为第二次中期分析,总生存数据尚未成熟;开放标签设计可能影响部分患者报告结局的解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related quality of life (QoL) versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer (NSCLC) at first interim analysis (99 events; median brigatinib follow-up, 11.0 months) in the open-label, phase III ALTA-1L trial (ClinicalTrials.gov identifier: NCT02737501). We report results of the second prespecified interim analysis (150 events). METHODS: Patients with ALK inhibitor-naive advanced ALK-positive NSCLC were randomly assigned 1:1 to brigatinib 180 mg once daily (7-day lead-in at 90 mg once daily) or crizotinib 250 mg twice daily. The primary end point was PFS as assessed by blinded independent review committee (BIRC). Investigator-assessed efficacy, blood samples for pharmacokinetic assessments, and patient-reported outcomes were also collected. RESULTS: Two hundred seventy-five patients were randomly assigned (brigatinib, n = 137; crizotinib, n = 138). With median follow-up of 24.9 months for brigatinib (150 PFS events), brigatinib showed consistent superiority in BIRC-assessed PFS versus crizotinib (hazard ratio [HR], 0.49 [95% CI, 0.35 to 0.68]; log-rank P < .0001; median, 24.0 v 11.0 months). Investigator-assessed PFS HR was 0.43 (95% CI, 0.31 to 0.61; median, 29.4 v 9.2 months). No new safety concerns emerged. Brigatinib delayed median time to worsening of global health status/QoL scores compared with crizotinib (HR, 0.70 [95% CI, 0.49 to 1.00]; log-rank P = .049). Brigatinib daily area under the plasma concentration-time curve was not a predictor of PFS (HR, 1.005 [95% CI, 0.98 to 1.031]; P = .69). CONCLUSION: Brigatinib represents a once-daily ALK inhibitor with superior efficacy, tolerability, and QoL over crizotinib, making it a promising first-line treatment of ALK-positive NSCLC.
引用
- Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020. PMID: 32780660. doi:10.1200/JCO.20.00505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。